Lifeboat Foundation

2 November 2016. Two companies partnering with Auburn University developed a synthetic virus to find and destroy tumor cells in a type of bone cancer in dogs. Financial and intellectual property aspects of the agreement between synthetic gene company Gen9 in Cambridge, Massachusetts, design systems developer Autodesk Inc. in San Rafael, California, and Auburn University College of Veterinary Medicine in Alabama were not disclosed.

The research team created a synthetic version of canine adenovirus type 2, or CAV2, a virus usually associated with hepatitis in dogs. In this case, the synthetic CAV-2 virus is designed as an oncolytic virus that finds and attacks cancer cells, while leaving healthy cells and tissue intact. The genome in the organism is believed to be the longest in a functional virus synthesized for cancer research, with about 34,000 base pairs of nucleic acids. The human genome, by comparison, has about 3 billion base pairs.

The technology provided by Gen9 in this project makes it possible to eventually produce synthetic therapeutic viruses tailored for specific patients. Gen9 offers customized gene synthesis and is developing a library of synthesized proteins and antibodies. One of the 4 year-old company’s founders is George Church, a geneticist at Harvard Medical School and serial entrepreneur. In August 2016, as reported in Science & Enterprise, Church and colleagues, including those from Gen9, developed a synthetic E. coli bacteria genome with redundant DNA components removed.

Scientists have been working for decades on engineered viruses that can hunt down and get inside cancer cells, cause them to burst and spur the immune system to mop up whatever malignant cells might be left behind. Only one such treatment has successfully become an FDA-approved cancer treatment.

That one drug, from Amgen, isn’t selling much. But that small victory a year ago has emboldened others to go forward with their own ideas to advance this approach to cancer therapy, known as oncolytic virus therapy.

One of the aspiring players in the oncolytic virus field, Ottawa, Canada-based Turnstone Biologics, is announcing today it has raised $41.4 million in a Series B venture financing. The round was led by OrbiMed Advisors, and included F-Prime Capital Partners and a couple of existing investors, FACIT and Versant Ventures. The new money will add on to the $11.3 million Series A round from a year ago.

Continue reading “Engineering Viruses to Kill Cancer Cells, Canada-Based Turnstone Raises $41.4M” »

From time to time, the Singularity Hub editorial team unearths a gem from the archives and wants to share it all over again. It’s usually a piece that was popular back then and we think is still relevant now. This is one of those articles. It was originally published October 25th, 2015. We hope you enjoy it!

Researchers at the University of Houston have reported a new method for inducing superconductivity in non-superconducting materials, demonstrating a concept proposed decades ago but never proven.

The technique can also be used to boost the efficiency of known superconducting materials, suggesting a new way to advance the commercial viability of superconductors, said Paul C.W. Chu, chief scientist at the Texas Center for Superconductivity at UH (TcSUH) and corresponding author of a paper describing the work, published Oct. 31 in the Proceedings of the National Academy of Sciences.

“Superconductivity is used in many things, of which MRI (magnetic resonance imaging) is perhaps the best known,” said Chu, the physicist who holds the TLL Temple Chair of Science at UH. But the technology used in health care, utilities and other fields remains expensive, in part because it requires expensive cooling, which has limited widespread adoption, he said.

Continue reading “Physicists induce superconductivity in non-superconducting materials” »

Come “ask me anything” right now!!! I’m trying to answer all questions I get asked:

Hi Reddit,

Thank you for having me here. My name is Zoltan Istvan, and I’m a futurist, journalist, and science fiction writer. I’m also the 2016 Presidential candidate for the Transhumanist Party.

Continue reading “AMA: I’m Zoltan Istvan, a transhumanist US Presidential Candidate. Ask me anything!! : Futurology” »

Everything you wanted to know about gene editing but were affraid to ask!

Researchers at the University of California in San Diego have found a way to use gene editing technology to target RNA in living cells.

Aging leads to diseases and ultimately death. Time for people to ditch the semantics and recognise that aging and disease are not two mysterious independent processes but are in fact one and the same.

Aging leads to the diseases of aging and the discussion is largely a matter of semantics.

“The concept of aging is undergoing a rapid transformation in medicine. The question has long been asked: Is aging a natural process that should be accepted as inevitable, or is it pathologic, a disease that should be prevented and treated? For the vast majority of medicine’s history, the former position was considered a self-evident truth. So futile was any attempt to resist the ravages of aging that the matter was relegated to works of fantasy and fiction. But today, the biomedical community is rethinking its answer to this question.

Continue reading “Aging, Just Another Disease” »

Science is making progress on the treatment of aging and age-releated diseases but should you rush out and start your own testing or not? This article weighs up some of the pros and cons.

Senescent cells accumulate with age, and secrete an unfortunate combination of signals that harms organs and tissues in numerous ways, such as via the production of increased chronic inflammation. This is one of the root causes of aging and age-related disease. Safe and effective clearance of senescent cells has been on the SENS rejuvenation biotechnology agenda for fifteen years, but only recently has progress in scientific funding and demonstrations of improved health and life spans in mice snowballed to the point at which startup companies could make a real go of it. Things are moving fairly rapidly in this field now. With the recent $116 million venture investment in UNITY Biotechnology’s work on senescent cell clearance, and other companies angling for their own launch, it is fair to say that this line of research and development is underway for real. Clinical trials of senescent cell clearance will be underway soon, funded by UNITY Biotechnology, and using drug candidates such as navitoclax developed in the cancer research community, noted for their ability to induce apoptosis, a form of programmed cell death. Senescent cells are primed for apoptosis, and it takes little to tip them over the edge in comparison to a normal somatic cell, which means that there may well be quite a large stable of existing drugs that will have some useful effect.

The question here is one that is only now starting to be useful to ask: should we all be running out today to obtain and take a drug (such as navitoclax) or drug combination (such as dasatinib and quercetin) that were shown to clear some fraction of senescent cells in rodents? Certainly there have been no shortage of people chasing after whatever the current hype of the day was in past years; I’m sure you all recall resveratrol and other alleged calorie restriction mimetics or telomere length enhancers. All a waste of time and effort. The difference between the science behind those and the science between senescent cell clearance is considerable, however. The items of the past have all been associated with altering metabolism so as to modestly slow aging, at best, and we have the very good examples of calorie restriction and exercise to show us the immediate bounds of the plausible on that front in our species.

Continue reading “On the Topic of Senescent Cells: Should We All be Trying to Take Navitoclax?” »

The SRF November newsletter is out now!

SENS Research Foundation email newsletter from 1st November 2016.